BOSTON, Jan. 22,
2024 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced the appointment of Darcy Mootz,
Ph.D., to its Board of Directors. Dr. Mootz is an experienced life
sciences executive, who brings expertise across corporate strategy,
corporate development, finance, and operations to Elevation
Oncology's Board of Directors.
"We are pleased to welcome Darcy to the Elevation Oncology
board, as she is a uniquely qualified leader, who has experience
crafting late-stage development strategies, advancing products
towards approval and launching new medicines for the treatment of
cancer," said Steve Elms, Managing
Partner of Aisling Capital and Chairman of Elevation Oncology.
"In addition, her broad expertise complements the strengths and
skills of Elevation Oncology's Board of Directors, and I am
confident she will provide important perspective as we continue to
advance EO-3021 through clinical development. We look forward to
Darcy's many contributions."
"I am honored to join the Elevation Oncology board," commented
Dr. Mootz. "Based on data presented by Elevation Oncology's
partner, I believe EO-3021 is a highly differentiated, potential
best-in-class anti-Claudin 18.2 ADC with the potential to transform
the care of patients with gastric cancer and other cancer types. I
am excited to partner with the team to advance this program and
build a pipeline of selective cancer therapies for a range of unmet
medical needs."
Dr. Mootz currently serves as President of Architect
Therapeutics, a position she has held since April 2023. She previously served as Head of
Amunix Pharmaceuticals from February
2022 until April 2023 and was
Chief Business Officer of Amunix from February 2019 to February
2022. Prior to joining Amunix, Dr. Mootz was an independent
consultant working with venture capital firms and life sciences
companies on corporate development and strategy projects. Before
that, she served as Chief Business Officer of ORIC Pharmaceuticals,
and, earlier, served as Vice President, Corporate Development at
Achaogen. In addition to the Elevation Oncology Board, Dr. Mootz
also serves on the Board of Directors of Alpha-9 Oncology. She
received a B.S. in Biology from Duke
University and a Ph.D. in Biochemistry from Harvard University.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class antibody drug conjugate (ADC)
designed to target Claudin 18.2, a clinically validated molecular
target. EO-3021 selectively delivers a cytotoxic payload directly
to cancer cells expressing Claudin 18.2. We are evaluating EO-3021
in a Phase 1 study in patients with advanced, unresectable or
metastatic solid tumors likely to express Claudin 18.2 including
gastric, gastroesophageal, pancreatic or esophageal cancers. We are
also exploring other opportunities through new or existing
partnerships and business development opportunities to expand our
oncology pipeline. For more information, visit
https://ElevationOncology.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated clinical and preclinical development
activities, potential benefits of Elevation Oncology's product
candidates, potential market opportunities for Elevation Oncology's
product candidates and the ability of Elevation Oncology's product
candidates to treat their targeted indications. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. These forward-looking
statements may be accompanied by such words as "aim," "anticipate,"
"believe," "could," "estimate," "expect," "forecast," "goal,"
"intend," "may," "might," "plan," "possible," "potential," "will,"
"would," and other words and terms of similar meaning. Although
Elevation Oncology believes that the expectations reflected in such
forward-looking statements are reasonable, Elevation Oncology
cannot guarantee future events, results, actions, levels of
activity, performance or achievements, and the timing and results
of biotechnology development and potential regulatory approval are
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause Elevation Oncology's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to Elevation Oncology's ability to advance its product
candidates, the timing and results of preclinical studies and
clinical trials, approvals and commercialization of product
candidates, the receipt and timing of potential regulatory
designations, Elevation Oncology's ability to fund development
activities and achieve development goals, Elevation Oncology's
ability to protect intellectual property, Elevation Oncology's
ability to establish and maintain collaborations with third
parties, and other risks and uncertainties described under the
heading "Risk Factors" in documents Elevation Oncology files from
time to time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and Elevation Oncology undertakes no obligation to revise
or update any forward-looking statements to reflect events or
circumstances after the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-announces-appointment-of-darcy-mootz-phd-to-its-board-of-directors-302039779.html
SOURCE Elevation Oncology